Manmeet S Ahluwalia Selected Research

Brain Neoplasms (Brain Tumor)

2/2022	Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
1/2022	Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases.
1/2022	Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.
1/2022	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
1/2022	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases.
1/2022	Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.
11/2021	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States.
11/2021	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance.
9/2021	Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases.
7/2021	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manmeet S Ahluwalia Research Topics

Disease

58	Brain Neoplasms (Brain Tumor) 02/2022 - 11/2013
56	Neoplasms (Cancer) 06/2022 - 01/2010
33	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 05/2006
23	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2014
19	Glioma (Gliomas) 07/2022 - 01/2010
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2010
14	Breast Neoplasms (Breast Cancer) 01/2020 - 09/2005
12	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2016
11	Melanoma (Melanoma, Malignant) 01/2020 - 01/2016
9	Necrosis 01/2022 - 11/2013
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 12/2017
4	Lymphoma (Lymphomas) 03/2020 - 07/2010
3	Disease Progression 01/2020 - 05/2010
3	Edema (Dropsy) 01/2017 - 06/2013
2	Oligodendroglioma 01/2022 - 03/2015
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2019
2	Thrombocytopenia (Thrombopenia) 01/2019 - 01/2018
2	Exanthema (Rash) 01/2019 - 05/2010
2	Central Nervous System Diseases (CNS Diseases) 10/2018 - 01/2018
2	Residual Neoplasm 08/2018 - 09/2010
2	Hemorrhage 04/2018 - 06/2016
2	Kidney Neoplasms (Kidney Cancer) 01/2018 - 01/2016
2	Adenocarcinoma 01/2018 - 07/2017
2	Neurologic Manifestations (Neurological Manifestations) 08/2017 - 12/2016
1	Nervous System Diseases (Neurological Disorders) 01/2022
1	Adenocarcinoma of Lung 01/2022
1	Circulating Neoplastic Cells 01/2022
1	Astrocytoma (Pilocytic Astrocytoma) 01/2022
1	Diffuse Scleroderma (Progressive Systemic Sclerosis) 03/2020
1	Meningeal Carcinomatosis 01/2020
1	Gastritis 01/2019

Drug/Important Bio-Agent (IBA)

13	Temozolomide (Temodar)FDA LinkGeneric 07/2022 - 05/2010
11	Immune Checkpoint InhibitorsIBA 01/2022 - 11/2015
9	ErbB Receptors (EGF Receptor)IBA 01/2022 - 05/2010
9	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2013
7	Pharmaceutical PreparationsIBA 01/2020 - 07/2010
7	Tyrosine Kinase InhibitorsIBA 01/2019 - 02/2010
6	SteroidsIBA 01/2022 - 06/2013
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 10/2012
5	Biological ProductsIBA 01/2022 - 01/2020
4	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2016
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2019
3	Peptides (Polypeptides)IBA 01/2020 - 08/2010
3	Monoclonal AntibodiesIBA 11/2017 - 01/2013
2	B7-H1 AntigenIBA 01/2022 - 01/2021
2	Lomustine (CCNU)FDA Link 01/2022 - 02/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2021 - 01/2017
2	EnzymesIBA 01/2021 - 01/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 01/2019
2	human ERBB2 proteinIBA 01/2020 - 01/2019
2	Lapatinib (GW572016)FDA Link 01/2019 - 01/2019
2	LigandsIBA 01/2019 - 08/2010
2	Trastuzumab (Herceptin)FDA Link 01/2019 - 10/2005
2	TOR Serine-Threonine KinasesIBA 01/2018 - 09/2015
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2017 - 01/2015
2	SurvivinIBA 11/2016 - 08/2010
2	cediranib (AZD2171)IBA 10/2015 - 02/2011
2	Sunitinib (Sutent)FDA Link 09/2015 - 02/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2013 - 05/2010
1	terameprocolIBA 02/2022
1	Circulating Tumor DNAIBA 01/2022
1	Endothelial Growth FactorsIBA 01/2022
1	RadiumIBA 01/2022
1	Vincristine (Oncovin)FDA LinkGeneric 01/2022
1	Procarbazine (Matulane)FDA Link 01/2022
1	cyclo(Arg-Pro) (CI 4)IBA 11/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 01/2021
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 12/2020
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 03/2020
1	NivolumabIBA 01/2020
1	macrophage migration inhibitory factor receptorIBA 01/2020
1	paclitaxel-Angiopep-2 conjugateIBA 01/2020
1	Capecitabine (Xeloda)FDA Link 11/2019
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 09/2019
1	iniparibIBA 01/2019
1	APTIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 11/2018
1	Messenger RNA (mRNA)IBA 11/2018
1	osimertinibIBA 10/2018
1	O-(6)-methylguanineIBA 08/2018
1	MethyltransferasesIBA 08/2018
1	DNA (Deoxyribonucleic Acid)IBA 08/2018

Therapy/Procedure

60	Therapeutics 07/2022 - 07/2004
36	Radiotherapy 06/2022 - 05/2006
17	Immunotherapy 01/2022 - 01/2013
15	Drug Therapy (Chemotherapy) 01/2022 - 10/2011
3	Combined Modality Therapy 01/2022 - 11/2013
2	Re-Irradiation 06/2022 - 11/2017
2	Precision Medicine 01/2019 - 11/2018
2	Lasers (Laser) 01/2014 - 06/2013
2	Molecular Targeted Therapy 01/2013 - 09/2012
1	Brachytherapy 01/2022
1	Investigational Therapies (Experimental Therapy) 01/2022
1	Craniotomy 11/2021
1	Length of Stay 11/2021
1	Patient Readmission 11/2021
1	Laser Therapy (Surgery, Laser) 12/2019
1	Complementary Therapies (Alternative Medicine) 10/2018
1	Catheters 04/2018